NO975608L - Neuroaktive steroider av androstan og pregnan serier - Google Patents

Neuroaktive steroider av androstan og pregnan serier

Info

Publication number
NO975608L
NO975608L NO975608A NO975608A NO975608L NO 975608 L NO975608 L NO 975608L NO 975608 A NO975608 A NO 975608A NO 975608 A NO975608 A NO 975608A NO 975608 L NO975608 L NO 975608L
Authority
NO
Norway
Prior art keywords
derivatives
series
grc
alpha
hydroxy
Prior art date
Application number
NO975608A
Other languages
English (en)
Other versions
NO311805B1 (no
NO975608D0 (no
Inventor
Ravindra B Upasani
David B Fick
Derk J Hogenkamp
Nancy C Lan
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of NO975608D0 publication Critical patent/NO975608D0/no
Publication of NO975608L publication Critical patent/NO975608L/no
Publication of NO311805B1 publication Critical patent/NO311805B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19975608A 1995-06-06 1997-12-04 Neuroaktive steroider av androstan- og pregnanserien, samt farmasöytiske preparater omfattende slike forbindelser NO311805B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46740495A 1995-06-06 1995-06-06
PCT/US1996/010115 WO1996040043A2 (en) 1995-06-06 1996-06-06 Neuroactive steroids of the androstane and pregnane series

Publications (3)

Publication Number Publication Date
NO975608D0 NO975608D0 (no) 1997-12-04
NO975608L true NO975608L (no) 1998-02-06
NO311805B1 NO311805B1 (no) 2002-01-28

Family

ID=23855552

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975608A NO311805B1 (no) 1995-06-06 1997-12-04 Neuroaktive steroider av androstan- og pregnanserien, samt farmasöytiske preparater omfattende slike forbindelser

Country Status (23)

Country Link
US (1) US5925630A (no)
EP (2) EP0837874B1 (no)
JP (1) JP4145350B2 (no)
KR (1) KR19990022323A (no)
CN (1) CN1190404A (no)
AT (1) ATE284895T1 (no)
AU (1) AU725214B2 (no)
BR (1) BR9608592A (no)
CA (1) CA2223996A1 (no)
CZ (1) CZ394197A3 (no)
DE (1) DE69634039T2 (no)
ES (1) ES2235187T3 (no)
FI (1) FI974448A (no)
GE (1) GEP20012530B (no)
HU (1) HUP9901138A3 (no)
IL (1) IL122348A0 (no)
NO (1) NO311805B1 (no)
NZ (1) NZ310850A (no)
PL (1) PL185523B1 (no)
PT (1) PT837874E (no)
RU (1) RU2194712C2 (no)
UA (1) UA57706C2 (no)
WO (1) WO1996040043A2 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
CA2372342A1 (en) * 1999-04-29 2000-11-09 Derk J. Hogenkamp 3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
EP1449846A1 (en) * 1999-04-29 2004-08-25 Euro-Celtique S.A. 3-alpha Hydroxy-3-beta methoxymethyl-21-heterocycle substituted steriods with anaesthetic activity
CA2386095A1 (en) * 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
WO2004089304A2 (en) * 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
WO2006110172A2 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals.Inc. Steroid analogs and characterization and treatment methods
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DK1868614T3 (da) * 2005-03-24 2012-11-12 Univ Emory Dosisregime til behandling af en traumatisk hjerneskade med progesteron
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
CA2833976C (en) * 2006-11-21 2016-03-15 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
US8969329B2 (en) * 2007-06-11 2015-03-03 University Of Southern California Allopregnanolone in a method for enhancing neurological function
US20100204192A1 (en) * 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2621282B1 (en) 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2014521662A (ja) * 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
CA2848212C (en) * 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN108976272B (zh) * 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
RU2019104004A (ru) 2012-01-23 2019-03-07 Сейдж Терапьютикс, Инк. Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
US20130281418A1 (en) * 2012-04-23 2013-10-24 Eric D. Marchewitz Use of hydroxypregnenolone derivatives for enhancing health and physical performance
CN102816198A (zh) * 2012-09-08 2012-12-12 广西师范学院 具有氨衍生物支链结构的3-羟基-5-烯甾体化合物制备方法及其在抗肿瘤药物中的应用
CN102924554B (zh) * 2012-10-29 2015-07-22 中国科学院昆明植物研究所 C-3,11,12,20-四取代c-21甾体类衍生物及其药物组合物和其在医药中的应用
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
ES2680582T3 (es) 2012-12-18 2018-09-10 Washington University Esteroides 19-alcoxi-17-sustituidos neuroactivos, profármacos de los mismos y métodos de tratamiento con los mismos
US10202413B2 (en) 2013-02-15 2019-02-12 Washington University Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
BR112015022174B1 (pt) 2013-03-13 2022-07-05 Sage Therapeutics, Inc Compostos esteróides neuroativos, sua composição farmacêutica e seu uso
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
KR20230172622A (ko) 2013-04-17 2023-12-22 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
WO2014169836A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
HUE051403T2 (hu) 2013-04-17 2021-03-01 Sage Therapeutics Inc Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz
PT3021852T (pt) 2013-07-19 2021-04-21 Sage Therapeutics Inc Esteroides neuroativos, composições e utilizações das mesmas
CA2921512A1 (en) * 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PE20180483A1 (es) 2015-07-06 2018-03-07 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
ES2884086T3 (es) 2015-07-06 2021-12-10 Sage Therapeutics Inc Oxisteroles y sus procedimientos de uso
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RS62222B1 (sr) 2016-07-07 2021-09-30 Sage Therapeutics Inc 24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda
RU2019103590A (ru) * 2016-07-11 2021-02-11 Сейдж Терапьютикс, Инк. С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
CN106265685A (zh) * 2016-09-18 2017-01-04 南通大学 没药甾酮z在制备抗抑郁症药物中的应用
AU2017337121B2 (en) 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
CN110072874B (zh) 2016-10-18 2022-08-12 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
JP2021510695A (ja) 2018-01-12 2021-04-30 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア−プレグナン−２０−オン−３α−オール化合物
BR112020016269A2 (pt) * 2018-02-11 2020-12-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Reguladores derivados de esteroides, método para prepará- los e suas utilizações
MX2020008182A (es) * 2018-02-11 2020-09-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos.
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN116425819A (zh) * 2019-01-08 2023-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
JP2022534424A (ja) 2019-05-31 2022-07-29 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
IL296371A (en) * 2020-03-18 2022-11-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
BR112022023428A2 (pt) * 2020-05-18 2023-01-17 Vistagen Therapeutics Inc Tratamento do transtorno de adaptação
RU2739247C1 (ru) * 2020-09-14 2020-12-22 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Способ получения лекарственного препарата для парентерального применения
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1050765B (de) * 1959-02-19 Les Laboratoires Fran?ais de Chimiotherapie, Paris Verfahren zur Herstellung von Testan-3a-ol-ll-on und seinen Estern
GB839911A (en) * 1957-01-29 1960-06-29 Chimiotherapie Lab Franc Derivatives of etiocholane and the preparation thereof
US3135744A (en) * 1961-04-12 1964-06-02 Vismara Francesco Spa Cycloalkenyl ethers of 17 beta-hydroxy androstanes
FR1437361A (fr) * 1962-06-28 1966-05-06 Vismara Francesco Spa Procédé de préparation de nouveaux éthers alcényliques de 17beta-hydroxy-androstanes
US3316146A (en) * 1964-03-30 1967-04-25 Upjohn Co Method of inducing sedation and muscle relaxation
GB1376892A (en) * 1970-11-12 1974-12-11 Glaxo Lab Ltd 2beta-substituted-3alpha-hydroxysteroids and their esters
US3969345A (en) * 1970-12-17 1976-07-13 Glaxo Laboratories Limited 20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
GB1377608A (en) * 1970-12-17 1974-12-18 Glaxo Lab Ltd 3alpha-hydroxy or acyloxy pregnene-21-ethers
US3943124A (en) * 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1380248A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy steroids and esters thereof
GB1409239A (en) * 1971-11-11 1975-10-08 Glaxo Lab Ltd Process for the preparation of 3alpha-hydroxy-5alpha-steroids
US3959260A (en) * 1972-05-05 1976-05-25 Glaxo Laboratories Limited Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
GB1432135A (en) * 1972-05-05 1976-04-14 Glaxo Lab Ltd 21-substituted pregnanes
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
US4192871A (en) * 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4297350A (en) * 1978-10-10 1981-10-27 The Upjohn Company Male contraceptive steroids and methods of use
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
JP4066272B2 (ja) * 1994-02-14 2008-03-26 ユーロ‐セルティック エス． ア． Ｇａｂａ受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
AU707486B2 (en) * 1994-11-23 1999-07-08 Euro-Celtique S.A. Androstane and pregnane series for allosteric modulation of gaba receptor

Also Published As

Publication number Publication date
DE69634039T2 (de) 2005-12-08
AU6172596A (en) 1996-12-30
HUP9901138A3 (en) 1999-11-29
EP0837874A2 (en) 1998-04-29
WO1996040043A2 (en) 1996-12-19
NO311805B1 (no) 2002-01-28
EP1288220A3 (en) 2004-07-21
FI974448A0 (fi) 1997-12-05
CA2223996A1 (en) 1996-12-19
PT837874E (pt) 2005-03-31
ES2235187T3 (es) 2005-07-01
IL122348A0 (en) 1998-04-05
ATE284895T1 (de) 2005-01-15
FI974448A (fi) 1997-12-05
WO1996040043A3 (en) 1997-03-27
PL185523B1 (pl) 2003-05-30
EP1288220A2 (en) 2003-03-05
UA57706C2 (uk) 2003-07-15
PL323718A1 (en) 1998-04-14
EP0837874B1 (en) 2004-12-15
RU2194712C2 (ru) 2002-12-20
GEP20012530B (en) 2001-09-25
HUP9901138A2 (hu) 1999-07-28
NO975608D0 (no) 1997-12-04
JP4145350B2 (ja) 2008-09-03
NZ310850A (en) 1999-07-29
KR19990022323A (ko) 1999-03-25
JPH11507643A (ja) 1999-07-06
AU725214B2 (en) 2000-10-05
MX9709384A (es) 1998-10-31
US5925630A (en) 1999-07-20
CN1190404A (zh) 1998-08-12
DE69634039D1 (de) 2005-01-20
CZ394197A3 (cs) 1998-06-17
BR9608592A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
NO975608D0 (no) Neuroaktive steroider av androstan og pregnan serier
DE69327096D1 (de) 17-substituierte steroide, verwendbar bei behandlung von krebs
ES2132249T3 (es) Procedimiento de preparacion de pregnanos 3-alfa-hidroxi,3-beta sustituidos.
ATE185812T1 (de) 17-spiromethylensteroide
DE69205405D1 (de) 17-Spirofuran-3'-Yliden Steroide.
IE44473L (en) 6,9,21-trihalo pregnanes
PT78743A (de) 1-alkyl-androsta-1,4-dien-3,17-dione verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
ATE152119T1 (de) Neue 16-methyl substituierte steroidderivate von pregna-1,4-dien-3,20-dion, ihre herstellung, ihre verwendung zur herstellung von 16-methylene- substituierte steroide und neue zwischenprodukten dafür
DE69126622D1 (de) 2beta,19-methylenamin überbrückte steroide als aromatasehemmer
DE60014096D1 (de) Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide
JPS51149258A (en) A process for preparing steroid derivatives
WO1990015067A3 (fr) NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES
NO944999L (no) Fremgangsmåte for steroide peracylglykosider
GB1267398A (en) PROCESS FOR THE MANUFACTURE OF 11beta-HYDROXY-5alpha,6alpha-EPOXY-STEROIDS

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees